Phase 1Recruiting
A Trial of Selinexor, Ruxolitinib and Methylprednisolone (KPT-IST-391)
A Phase I Trial of Selinexor, Ruxolitinib and Methylprednisolone for Patients With Relapsed/Refractory Multiple Myeloma
- Sponsor
- Oncotherapeutics (Industry)
- Enrollment
- 30 planned
- Conditions
- Multiple Myeloma in Relapse; Multiple Myeloma, Refractory
- Interventions
- Selinexor; Ruxolitinib; Methylprednisolone
- Ages
- children, adults, older adults
- Registry
- NCT06225310
Full record on ClinicalTrials.gov
From the registry
Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies. It functions by inhibiting the nuclear export protein XPO1, resulting in the accumulation of tumor suppressor proteins and inhibition of oncoprotein mRNAs, which is selectively lethal to myeloma cells. Selinexor has demonstrated activity in combination with various drugs, including glucocorticoids and proteasome inhibitors, leading to its FDA approval for the treatment of relapsed or refractory multiple myeloma.
Primary outcomes
- 1. Maximum Tolerated Dose (MTD):
- 2. Recommended phase 2 dose (RP2D)
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered